First Potential Lupus-Specific Treatment in Sight!

Today, Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) announced positive results from a year-long clinical trial of BENLYSTA for treating lupus. When the 52-week study concluded, the lupus patients who were treated with BENLYSTA had improvement. The patients receiving BENLYSTA also were able to reduce their intake of steroid medications. The study is the largest ever for lupus.

With no new drugs for more than 50 years, The Lupus Foundation of America is greatly encouraged by the results.  An estimated 1.5 million Americans and more than 5 million people worldwide live with lupus.

Should the FDA ultimately approve BENLYSTA, it would become the first drug successfully developed to treat lupus since the disease was discovered more than a century ago.  Assuming positive results in November from second Phase 3 trial of BENLYSTA, companies plan to submit marketing applications in the U.S., Europe and other regions in the first half of 2010.

Fore more information on BENLYSTA click HERE.

If you or someone you know has been denied long-term disability benefits for their claim for Lupus, please contact Stacey Burke of SMSH at (800) 282-2122.  Stacey is currently reprepsenting clients with denied claims for Lupus and other auto-immune diseases.